However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...